216 related articles for article (PubMed ID: 18068265)
1. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients.
Célestin Schartz NE; Chevret S; Paz C; Kerob D; Verola O; Morel P; Lebbé C
J Am Acad Dermatol; 2008 Apr; 58(4):585-91. PubMed ID: 18068265
[TBL] [Abstract][Full Text] [Related]
2. Treatment of genital warts with an immune-response modifier (imiquimod).
Beutner KR; Spruance SL; Hougham AJ; Fox TL; Owens ML; Douglas JM
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):230-9. PubMed ID: 9486679
[TBL] [Abstract][Full Text] [Related]
3. Topical imiquimod: a review of its use in genital warts.
Perry CM; Lamb HM
Drugs; 1999 Aug; 58(2):375-90. PubMed ID: 10473026
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma.
Peris K; Micantonio T; Fargnoli MC; Lozzi GP; Chimenti S
J Am Acad Dermatol; 2006 Aug; 55(2):324-7. PubMed ID: 16844522
[TBL] [Abstract][Full Text] [Related]
6. 5% topical imiquimod tolerance in transplant recipients.
Ben M'barek L; Mebazaa A; Euvrard S; Frances C; Thervet E; Morel P; Menasché S; Legendre C; Lebbe C
Dermatology; 2007; 215(2):130-3. PubMed ID: 17684375
[TBL] [Abstract][Full Text] [Related]
7. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis.
Persaud AN; Shamuelova E; Sherer D; Lou W; Singer G; Cervera C; Lamba S; Lebwohl MG
J Am Acad Dermatol; 2002 Oct; 47(4):553-6. PubMed ID: 12271300
[TBL] [Abstract][Full Text] [Related]
8. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.
Hoyme UB; Hagedorn M; Schindler AE; Schneede P; Hopfenmüller W; Schorn K; Eul A
Infect Dis Obstet Gynecol; 2002; 10(2):79-88. PubMed ID: 12530484
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
10. Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study.
Berman B; Harrison-Balestra C; Perez OA; Viera M; Villa A; Zell D; Ramirez C
J Drugs Dermatol; 2009 May; 8(5):455-8. PubMed ID: 19537368
[TBL] [Abstract][Full Text] [Related]
11. Experience in treating molluscum contagiosum in children with imiquimod 5% cream.
Bayerl C; Feller G; Goerdt S
Br J Dermatol; 2003 Nov; 149 Suppl 66():25-9. PubMed ID: 14616342
[TBL] [Abstract][Full Text] [Related]
12. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D
Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
14. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream.
Micali M; Nasca MR; Musumeci ML
Int J Tissue React; 2005; 27(3):111-4. PubMed ID: 16372477
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
16. Topical imiquimod 5% as a treatment for localized genital Kaposi's sarcoma in an HIV-negative man: a case report.
Fairley JL; Denham I; Yoganathan S; Read TR
Int J STD AIDS; 2012 Dec; 23(12):907-8. PubMed ID: 23258836
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms.
Harrison LI; Skinner SL; Marbury TC; Owens ML; Kurup S; McKane S; Greene RJ
Arch Dermatol Res; 2004 Jun; 296(1):6-11. PubMed ID: 15083310
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial.
Theos AU; Cummins R; Silverberg NB; Paller AS
Cutis; 2004 Aug; 74(2):134-8, 141-2. PubMed ID: 15379366
[TBL] [Abstract][Full Text] [Related]
19. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream.
Cowen E; Mercurio MG; Gaspari AA
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S240-8. PubMed ID: 12271286
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
